{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:05:40Z","timestamp":1793811940289,"version":"4.6.1"},"reference-count":50,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Investigators acknowledge the limitations of rodent or non-human primate stroke models, hundreds of putative neuroprotectants have been evaluated in preclinical models, but not one has entered the clinical realm. Initial studies focused on the neuron, but in recent years the focus has widened to also include other neural cells including astrocytes, pericytes and endothelial cells, which together form the neurovascular unit. Some new developments raise renewed hope for neuroprotection: the appearance of new compounds with multiple mechanisms of action, or the promulgation of new standards for a rigorous preclinical testing. At the bedside in the last 5 years, uric acid and nerinetide are the only compounds tested for clinical efficacy in randomised controlled trials (RCTs), where all patients had to receive reperfusion therapies, either intravenous thrombolysis and\/or mechanical thrombectomy. In addition, otaplimastat, 3K3A-activated protein C (APC), intra-arterial verapamil and intra-arterial hypothermia were also assessed in combination with reperfusion therapy, but in RCTs that only included feasibility or safety outcomes. Some of these compounds yielded promising results which are discussed in this review. Altogether, a deeper knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an improved preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove more effective than in the past to reverse a dismal situation that has lasted already too long.<\/jats:p>","DOI":"10.1136\/jnnp-2020-324283","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T22:21:16Z","timestamp":1604528476000},"page":"129-135","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":155,"title":["The future of neuroprotection in stroke"],"prefix":"10.1136","volume":"92","clinical-trial-number":[{"clinical-trial-number":"nct02315443","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02235558","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03394950","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-6285","authenticated-orcid":false,"given":"\u00c1ngel","family":"Chamorro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng H","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Ren\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"van Leyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D","family":"Lyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2021051303401002000_92.2.129.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804355"},{"key":"2021051303401002000_92.2.129.2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"key":"2021051303401002000_92.2.129.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00114-9"},{"key":"2021051303401002000_92.2.129.4","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.184"},{"key":"2021051303401002000_92.2.129.5","doi-asserted-by":"publisher","DOI":"10.1159\/000118039"},{"key":"2021051303401002000_92.2.129.6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12975-016-0469-3","article-title":"Improving reperfusion therapies in the era of mechanical thrombectomy","volume":"7","author":"Linfante","year":"2016","journal-title":"Transl Stroke Res"},{"key":"2021051303401002000_92.2.129.7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.chembiol.2020.03.007","article-title":"The chemical biology of ferroptosis in the central nervous system","volume":"27","author":"Ratan","year":"2020","journal-title":"Cell Chem Biol"},{"key":"2021051303401002000_92.2.129.8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1177\/0271678X18814614","article-title":"Differential effects of hypothermia on neurovascular unit determine protective or toxic results: toward optimized therapeutic hypothermia","volume":"39","author":"Lyden","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"2021051303401002000_92.2.129.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuint.2016.12.007","article-title":"Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke","volume":"107","author":"Davis","year":"2017","journal-title":"Neurochem Int"},{"key":"2021051303401002000_92.2.129.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23504-1","article-title":"Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia","volume":"8","author":"Tu","year":"2018","journal-title":"Sci Rep"},{"key":"2021051303401002000_92.2.129.11","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X15606722"},{"key":"2021051303401002000_92.2.129.12","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1161\/STROKEAHA.119.027359","article-title":"Dual antiplatelet therapy increases hemorrhagic transformation following thrombolytic treatment in experimental stroke","volume":"50","author":"Zheng","year":"2019","journal-title":"Stroke"},{"key":"2021051303401002000_92.2.129.13","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.014790"},{"key":"2021051303401002000_92.2.129.14","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017287"},{"key":"2021051303401002000_92.2.129.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm1735"},{"key":"2021051303401002000_92.2.129.16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pneurobio.2016.04.004","article-title":"Help-me signaling: non-cell autonomous mechanisms of neuroprotection and neurorecovery","volume":"152","author":"Xing","year":"2017","journal-title":"Prog Neurobiol"},{"key":"2021051303401002000_92.2.129.17","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005733"},{"key":"2021051303401002000_92.2.129.18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jnc.14337","article-title":"Effects of ischemic post-conditioning on neuronal VEGF regulation and microglial polarization in a rat model of focal cerebral ischemia","volume":"146","author":"Esposito","year":"2018","journal-title":"J Neurochem"},{"key":"2021051303401002000_92.2.129.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature18928"},{"key":"2021051303401002000_92.2.129.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.04.003"},{"key":"2021051303401002000_92.2.129.21","doi-asserted-by":"crossref","unstructured":"Mestre H , Du T , Sweeney AM , et al . Cerebrospinal fluid influx drives acute ischemic tissue swelling. Science 2020;367:eaax7171. doi:10.1126\/science.aax7171","DOI":"10.1126\/science.aax7171"},{"key":"2021051303401002000_92.2.129.22","doi-asserted-by":"crossref","unstructured":"Esposito E , Ahn BJ , Shi J , et al . Brain-to-cervical lymph node signaling after stroke. Nat Commun 2019;10:5306. doi:10.1038\/s41467-019-13324-w","DOI":"10.1038\/s41467-019-13324-w"},{"key":"2021051303401002000_92.2.129.23","doi-asserted-by":"crossref","unstructured":"Rajan WD , Wojtas B , Gielniewski B , et al . Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans. Neurobiol Dis 2020;137:104722. doi:10.1016\/j.nbd.2019.104722","DOI":"10.1016\/j.nbd.2019.104722"},{"key":"2021051303401002000_92.2.129.24","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baaa057","article-title":"Gliome database: a comprehensive web-based tool to access and analyze glia secretome data","volume":"2020","author":"Kim","year":"2020","journal-title":"Database"},{"key":"2021051303401002000_92.2.129.25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nbd.2018.07.021","article-title":"Effects of aging, hypertension and diabetes on the mouse brain and heart vasculomes","volume":"126","author":"Guo","year":"2019","journal-title":"Neurobiol Dis"},{"key":"2021051303401002000_92.2.129.26","first-page":"63","article-title":"Effects of hypertension and exercise in the brain and heart vasculome of rats","volume":"2","author":"Lan","year":"2019","journal-title":"Conditioning Med"},{"key":"2021051303401002000_92.2.129.27","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.020626"},{"key":"2021051303401002000_92.2.129.28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41586-020-2348-z","article-title":"Potential circadian effects on translational failure for neuroprotection","volume":"582","author":"Esposito","year":"2020","journal-title":"Nature"},{"key":"2021051303401002000_92.2.129.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171688","article-title":"Evolution of ischemic damage and behavioural deficit over 6 months after MCAO in the rat: selecting the optimal outcomes and statistical power for multi-centre preclinical trials","volume":"12","author":"Rewell","year":"2017","journal-title":"PLoS One"},{"key":"2021051303401002000_92.2.129.30","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017112"},{"key":"2021051303401002000_92.2.129.31","doi-asserted-by":"crossref","unstructured":"Aliena-Valero A , Rius-P\u00e9rez S , Baixauli-Mart\u00edn J , et al . Uric acid neuroprotection associated to IL-6\/STAT3 signaling pathway activation in rat ischemic stroke. Mol Neurobiol 2020;14.doi:10.1007\/s12035-020-02115-w","DOI":"10.1007\/s12035-020-02115-w"},{"key":"2021051303401002000_92.2.129.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70054-7"},{"key":"2021051303401002000_92.2.129.33","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009960"},{"key":"2021051303401002000_92.2.129.34","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24378"},{"key":"2021051303401002000_92.2.129.35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1747493016684354","article-title":"Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy","volume":"12","author":"\u00c1","year":"2017","journal-title":"Int J Stroke"},{"key":"2021051303401002000_92.2.129.36","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"The Lancet"},{"key":"2021051303401002000_92.2.129.37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ana.25644","article-title":"Safety and efficacy of Otaplimastat in patients with acute ischemic stroke requiring tPA (SAFE-tPA): a multicenter, randomized, double-blind, placebo-controlled phase 2 study","volume":"87","author":"Kim","year":"2020","journal-title":"Ann Neurol"},{"key":"2021051303401002000_92.2.129.38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.25383","article-title":"Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke","volume":"85","author":"Lyden","year":"2019","journal-title":"Ann Neurol"},{"key":"2021051303401002000_92.2.129.39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/bc.bc_25_19","article-title":"Evidence and opportunities of hypothermia in acute ischemic stroke: clinical trials of systemic versus selective hypothermia","volume":"5","author":"Huber","year":"2019","journal-title":"Brain Circ"},{"key":"2021051303401002000_92.2.129.40","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012727"},{"key":"2021051303401002000_92.2.129.41","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.223"},{"key":"2021051303401002000_92.2.129.42","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.001346"},{"key":"2021051303401002000_92.2.129.43","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199601000-00014"},{"key":"2021051303401002000_92.2.129.44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67284"},{"key":"2021051303401002000_92.2.129.45","doi-asserted-by":"crossref","unstructured":"Kubis N . Non-Invasive Brain Stimulation to Enhance Post-Stroke Recovery. Front Neural Circuits. 2016;10:56. Published 2016.","DOI":"10.3389\/fncir.2016.00056"},{"key":"2021051303401002000_92.2.129.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408827"},{"key":"2021051303401002000_92.2.129.47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1142\/S0192415X19500265","article-title":"A systematic review of neuroprotective efficacy and safety of DL-3-N-Butylphthalide in ischemic stroke","volume":"47","author":"Xu","year":"2019","journal-title":"Am J Chin Med"},{"key":"2021051303401002000_92.2.129.48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9346"},{"key":"2021051303401002000_92.2.129.49","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1187131"},{"key":"2021051303401002000_92.2.129.50","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1474-4422(16)30196-X","article-title":"Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Sheth","year":"2016","journal-title":"Lancet Neurol"}],"updated-by":[{"DOI":"10.1136\/jnnp-2020-324283corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000}}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-324283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T17:30:43Z","timestamp":1669483843000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-324283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jnnp-2020-324283"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-324283","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jnnp-2020-324283corr1","asserted-by":"object"}]},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}